ReviewExperimental eye research2021
Novel insights into gene therapy in the cornea.
Review in Experimental eye research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 55 citations in OpenAlex.
- Topical application of Cas9 ribonucleoproteins inhibits corneal neovascularization in a mouse model of alkali burn injury.Gene therapy · 2026Article
- Ocular Surface Inflammation as a Driver of Cornea Limbal Stem Cell Deficiency: Mechanisms and Implications.International journal of molecular sciences · 2026Review
- Alterations in Mitochondrial DNA in Corneal Fibroblast and Myofibroblast Post Injury.Investigative ophthalmology & visual science · 2026Article
- Long-Term Tolerability and Safety of AAV5-Id3 Gene Therapy to Eyes.Translational vision science & technology · 2026Article
- Progressive Insights into 3D Bioprinting for Corneal Tissue Restoration.Advanced healthcare materials · 2026Review
- Toward Precision Medicine: Gene Therapy Applications in the Management of Uveal Melanoma.Cancer reports (Hoboken, N.J.) · 2025Review
- Review
- Effect of Periplaneta americana Extract on Corneal Fibrosis and Epithelial Healing After Rabbit Lamellar Keratectomy.Translational vision science & technology · 2025Article
- From Pathophysiology to Innovative Therapies in Eye Diseases: A Brief Overview.International journal of molecular sciences · 2025Review
- Brittle Cornea Syndrome: Molecular Diagnosis and Management.Diagnostics (Basel, Switzerland) · 2025Article
- Review
- Transforming transplantation science: New advanced molecular strategy to overcome corneal graft rejection.Molecular therapy : the journal of the American Society of Gene Therapy · 2024Article
- Progranulin Facilitates Corneal Repair Through Dual Mechanisms of Inflammation Suppression and Regeneration Promotion.Inflammation · 2024Article
- Genome Editing VEGFA Prevents Corneal Neovascularization In Vivo.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Blast injury: Impact to the cornea.Experimental eye research · 2024Review
- Tissue Engineering and Ophthalmology.Turkish journal of ophthalmology · 2024Review
- Suppressing Pro-Apoptotic Proteins by siRNA in Corneal Endothelial Cells Protects against Cell Death.Biomedicines · 2024Article
- Methylation in cornea and corneal diseases: a systematic review.Cell death discovery · 2024Review
- [Gene therapy in ophthalmology].Die Ophthalmologie · 2023Review
- Ocular-Surface Regeneration Therapies for Eye Disorders: The State of the Art.Biotech (Basel (Switzerland)) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Corneal disease remains a leading cause of impaired vision world-wide, and advancements in gene therapy continue to develop with promising success to prevent, treat and cure blindness. Ideally, gene therapy requires a vector and gene delivery method that targets treatment of specific cells or tissues and results in a safe and non-immunogenic response. The cornea is a model tissue for gene therapy due to its ease of clinician access and immune-privileged state. Improvements in the past 5-10 years have begun to revolutionize the approach to gene therapy in the cornea with a focus on adeno-associated virus and nanoparticle delivery of single and combination gene therapies. In addition, the potential applications of gene editing (zinc finger nucleases [ZNFs], transcription activator-like effector nucleases [TALENs], Clustered Regularly Interspaced Short Palindromic Repeats/Associated Systems [CRISPR/Cas9]) are rapidly expanding. This review focuses on recent developments in gene therapy for corneal diseases, including promising multiple gene therapy, while outlining a practical approach to the development of such therapies and potential impediments to successful delivery of genes to the cornea.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.